The landscape of impurity control in pharmaceutical manufacturing has been profoundly reshaped by the emergence of N-nitrosamines as potent mutagenic impurities. Since the initial discovery of NDMA in sartan-based products in 2018, regulatory bodies have continuously refined their expectations to…